Benfotiamine for early Alzheimer's disease in a Phase II trial

Who could benefit from this research

What this research studies

This study continues an 18-month, randomized, placebo-controlled trial of benfotiamine for individuals in the early stages of Alzheimer’s disease. Researchers believe that boosting thiamine levels in the brain may improve metabolism, reduce brain inflammation, and lessen plaque and tangle pathology, potentially translating to better daily thinking and memory. The study builds on prior pilot data showing good tolerance and hints of cognitive benefit and aims to confirm these signals with more participants across a longer duration. Participants will receive either benfotiamine or placebo, with regular assessments of cognition, brain imaging, and biomarkers. If successful, this approach could become a new, safe oral treatment to slow progression in early Alzheimer’s disease.

Why it matters

Where this research is happening

• Weill Medical Coll of Cornell Univ
  New York, United States Active

Researchers

• Principal investigator: Gibson, Gary E — Weill Medical Coll of Cornell Univ
• Study coordinator: Gibson, Gary E

Related research

Other NIH-funded projects on the same topics.

• Ear health and memory: can hearing aids help prevent cognitive decline in adults at risk for Alzheimer's

  A focused study will test whether using hearing aids can help 55-75 year olds with early hearing loss keep their thinking sharper and reduce risk for Alzheimer’s-related changes.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11395476

• Move2Joy: a personalized mobile program to boost activity and lower dementia risk

  A mobile health program helps middle-aged and older adults stay physically active to reduce the chance of developing Alzheimer’s disease and related dementias.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11364577

• Using hearing aids to help protect memory and thinking in people with early hearing loss

  This trial will test whether providing hearing-aid based support to people aged 55–75 with early hearing loss and mild memory problems can slow memory decline and related brain changes linked to Alzheimer's disease.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11178762

• Investigating the effects of indoor cycling on slowing Alzheimer's disease progression in older adults at genetic risk.

  This study is looking at how high-intensity indoor cycling might help protect the brain health of healthy older adults aged 65 to 80 who have a specific gene linked to Alzheimer's disease, by comparing their cognitive function and brain scans before and after the exercise program.

  NIH research Cleveland Clinic Lerner Com-Cwru · Cleveland, United States · NIH-11009531

• Investigating how early hearing loss may relate to Alzheimer's disease

  This study is looking at how using hearing aids might help people aged 55 to 75 with early hearing loss and mild memory issues, by seeing if better hearing can improve their thinking skills and social connections, possibly helping to prevent further memory decline.

  NIH research Columbia University Health Sciences · New York, United States · NIH-10911957

• Benfotiamine for early Alzheimer's disease

  This trial tests whether benfotiamine, a form of vitamin B1, can improve memory and slow decline in people with early Alzheimer's disease.

  NIH research Winifred Masterson Burke Med Res Inst · White Plains, United States · NIH-10891398

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.